Jinghua Pharmaceutical Group Co., Ltd.

002349

CNE100000L14

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
6.69 ^CNY	+3.24%		0.00%	-24.58%

Jun. 12	Jinghua Pharmaceutical to Build Medicine Production Base for 1 Billion Yuan	MT
May. 20	Jinghua Pharmaceutical Group Co., Ltd. Announces Board and Supervisor Appointments	CI

Jinghua Pharmaceutical Group Co., Ltd. Announces Board and Supervisor Appointments

May 20, 2024 at 03:32 pm EDT

Jinghua Pharmaceutical Group Co., Ltd. announced that at the Annual General Meeting of 2023 held on 17 May 2024, approved election of Cheng Jian as non-independent director. Election of Liu Jing and Zhang Xiaomei as independent director. Election of Dai Chenguang as non-employee supervisor.

Latest news about Jinghua Pharmaceutical Group Co., Ltd.

Jinghua Pharmaceutical to Build Medicine Production Base for 1 Billion Yuan	Jun. 12	MT
Jinghua Pharmaceutical Group Co., Ltd. Announces Board and Supervisor Appointments	May. 20	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Jinghua Pharmaceutical's Unit Shuts Down Amid Water Pollution Probe	Apr. 18	MT
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
China COVID infection fears fuel medical stock bets	22-12-12	RE
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Jinghua Pharmaceutical Group Co., Ltd.(XSEC:002349) added to S&P Global BMI Index	22-09-19	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Jinghua Pharmaceutical's Controlling Shareholder Plans to Cut 2% Stake	22-04-08	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Three Chinese Drugmakers Deny Receiving Orders From Pfizer	22-02-14	MT
Nantong Jinghua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Haian Ruihai Urbanization Investment and Construction Co., Ltd., completed the acquisition of 10.29% stake in Nantong Jinghua Pharmaceutical Co., Ltd. from Zan Shengda.	21-10-18	CI
Jiangsu Qichen New Materials Co., Ltd. acquired 24.9% stake in Jiangsu Wannianchang Pharmaceutical Co., Ltd. from Nantong Jinghua Pharmaceutical Co., Ltd. for CNY 69.4 million.	21-09-28	CI
Nantong Jinghua Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
Haian Ruihai Urbanization Investment and Construction Co., Ltd., entered into a share purchase agreement to acquire 10.29% stake in Nantong Jinghua Pharmaceutical Co., Ltd. from Zan Shengda for approximately CNY 510 million.	21-08-19	CI
Nantong Jinghua Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-26	CI
FortuneRock Co., Ltd. announces an Equity Buyback for 679,000 shares, for CNY 5.78 million.	21-04-14	CI
FortuneRock Co., Ltd. authorizes a Buyback Plan.	21-04-12	CI
Nantong Jinghua Pharmaceutical Co., Ltd. Approves Executive Appointments	21-02-09	CI

Chart Jinghua Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Jinghua Pharmaceutical Group Co., Ltd.

More charts

Company Profile

JINGHUA PHARMACEUTICAL GROUP CO., LTD., formerly NANTONG JINGHUA PHARMACEUTICAL CO., LTD., is a China-based company, principally engaged in the research and development, production and distribution of Chinese patent drugs, pharm ingredients and intermediates and chemical intermediates. The Company is also engaged in the provision of traditional Chinese medicinal materials and Chinese herbal pieces, among others. The Company primarily provides tablets, capsules, pills, granules, injections, powder, syrup, healthcare products, beverages and chemical intermediates, among others. The Company offers Chinese patent medicines, such as Wangshi Baochiwan pills and Jidesheng tablets. Its bulk drugs include phenobarbitone and fluorouracil. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JINGHUA PHARMACEUTICAL GROUP CO., LTD.	-24.58%	725M
ELI LILLY AND COMPANY	+60.25%	846B
NOVO NORDISK A/S	+38.56%	628B
JOHNSON & JOHNSON	-4.49%	360B
MERCK & CO., INC.	+18.30%	322B
ABBVIE INC.	+9.64%	297B
ASTRAZENECA PLC	+14.15%	240B
ROCHE HOLDING AG	+3.11%	224B
NOVARTIS AG	+16.98%	223B
AMGEN INC.	+12.87%	173B